Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker
- 7 March 2014
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 67 (6) , 520-528
Abstract
Aims: To perform immunohistochemical (IHC) analysis of molecular drivers related to the development and maintenance of melanoma and to assess their value as diagnostic and prognostic melanoma biomarkers in routine clinical practice. Methods: Tissue microarrays constructed from a cohort of primary melanomas (n=355), benign naevi (n=37) and melanoma metastases (n=14) were evaluated for IHC expression of c-KIT, BRAFV600E, MITF, p16, p53 and PTEN, as well as for pERK, a surrogate marker for mitogen-activated protein kinase pathway activation. The results were correlated with clinicopathological parameters and clinical outcome. Results: Absent p16 expression and reduced MITF expression were both associated with the adverse prognostic markers ulceration (p=0.009 and p<0.0001, respectively), advanced tumour stage (p<0.0001 and p=0.001, respectively) and higher Breslow thickness (both p<0.0001), as well as with an adverse overall relapse-free survival (p<0.0001 and p=0.003, respectively). Absence of p16 expression predicted overall relapse-free (p=0.02) and distant metastasis-free (p=0.04) survival, independently of Breslow thickness, ulceration and tumour stage. Conclusions: IHC determined p16 expression is an independent prognostic biomarker of potential value in routine melanoma diagnostic practice.Keywords
This publication has 63 references indexed in Scilit:
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Melanoma genome sequencing reveals frequent PREX2 mutationsNature, 2012
- C-KIT Signaling Depends on Microphthalmia-Associated Transcription Factor for Effects on Cell ProliferationPLOS ONE, 2011
- Clinical Correlates of NRAS and BRAF Mutations in Primary Human MelanomaClinical Cancer Research, 2011
- Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic MelanomaClinical Cancer Research, 2009
- Genome-wide screen of promoter methylation identifies novel markers in melanomaGenome Research, 2009
- Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous MelanomaJournal of Investigative Dermatology, 2008
- The genome and epigenome of malignant melanomaAPMIS, 2007
- B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact PrognosisPLOS ONE, 2007
- Mutations of the BRAF gene in human cancerNature, 2002